Funding News
TRUE ARTIS Raises Rs 11.4 Crore in Seed Funding to Scale India's First Integrated Aesthetic Healthcare and Surgical Platform Across Delhi NCR
By Mustafa Shariff, Editor in Chief · September 22, 2026 · 2 mins read
Summary
- TRUE ARTIS Raises Rs 11.4 Crore Seed Led by Zeropearl VC — India's Integrated Aesthetic Healthcare Platform Scales Across Delhi NCR
- TRUE ARTIS raised Rs 11.4 crore seed funding from Zeropearl VC (September 2026) to expand its integrated aesthetic healthcare and surgical platform across Delhi NCR — building quality-standardised aesthetic medicine infrastructure for India's growing cosmetic procedure market.
"Aesthetic medicine in India is at the same inflection point that dental care was ten years ago — fragmented, inconsistent in quality, and dramatically underserved relative to the latent demand. TRUE ARTIS is building the integrated platform that the aesthetic healthcare sector needs: standardised clinical protocols, technology-enabled patient journey management, curated surgeon networks, and the kind of quality assurance that makes aesthetic procedures safe and predictable rather than a roll of the dice. The Rs 11.4 crore seed round from Zeropearl VC gives us the capital to prove the model in Delhi NCR and then replicate it across India's metros."
TRUE ARTIS, an integrated Indian aesthetic healthcare and surgical platform, raised Rs 11.4 crore in a seed funding round led by Zeropearl VC in September 2026, as the company looks to expand its clinical operations and technology platform across Delhi NCR.
What TRUE ARTIS Is Building
TRUE ARTIS is building an integrated platform for aesthetic medicine and surgical procedures — combining a curated network of aesthetic surgeons and practitioners, technology-enabled patient journey management (from initial consultation through procedure and post-procedure follow-up), standardised clinical protocols, and quality assurance infrastructure. The platform targets the specific problem that characterises India's aesthetic medicine market: fragmentation and inconsistency. A patient seeking a cosmetic procedure in India faces a market with no quality standards, no standardised pricing, no outcome benchmarks, and no way to reliably distinguish clinically rigorous practitioners from those who are not.
India's Aesthetic Medicine Market
India's aesthetic medicine market — spanning non-surgical procedures (dermal fillers, botulinum toxin injections, laser treatments, chemical peels, PRP therapy) and surgical procedures (rhinoplasty, blepharoplasty, liposuction, breast augmentation) — is one of the fastest-growing healthcare sub-sectors in India. The drivers: rising disposable incomes among India's urban middle class, social media influence normalising aesthetic procedures (particularly among India's 18-35 demographic), growing acceptance of both non-surgical and surgical aesthetic treatments, and an increasingly image-conscious consumer culture across metro and Tier-1 cities.
The market suffers from a quality and trust problem that holds back adoption among consumers who might otherwise seek procedures: the absence of standardised quality benchmarks means that patient outcomes are highly variable even for the same procedure type. TRUE ARTIS's integrated platform model — standardised protocols, curated practitioners, technology-enabled patient journey, outcome monitoring — is the quality infrastructure that the market lacks and patients increasingly demand.
Delhi NCR First, Multi-City Replication
The Rs 11.4 crore seed round will fund TRUE ARTIS's expansion across Delhi NCR — India's largest metro by population and one of its largest aesthetic medicine markets. Delhi NCR's concentration of dermatology clinics, aesthetic surgery centres, and medical spas creates a dense market environment where the platform model can demonstrate its clinical and commercial value before replication across Mumbai, Bengaluru, and other metros.
BHC Perspective
At Bengaluru Health Community, TRUE ARTIS's seed round is a story in a healthcare sub-sector BHC Media has not previously covered: aesthetic medicine platform technology. For BHC founders in clinical platform technology, patient journey management, or quality-standardisation infrastructure for fragmented healthcare sectors — TRUE ARTIS's seed-stage platform model in aesthetic medicine is directly analogous to the quality standardisation opportunity that exists across multiple fragmented Indian healthcare categories.
FAQs
Q: What is TRUE ARTIS?
A: An integrated Indian aesthetic healthcare and surgical platform building technology-enabled, quality-standardised infrastructure for cosmetic medicine and surgical procedures. Raised Rs 11.4 crore seed from Zeropearl VC (September 2026) to expand across Delhi NCR.
Q: Why is India's aesthetic medicine market an opportunity?
A: Rising disposable incomes, social media normalisation of cosmetic procedures, growing acceptance across metro India — but the market is deeply fragmented with no quality standards or outcome benchmarks. TRUE ARTIS provides the quality infrastructure (standardised protocols, curated practitioners, tech-enabled patient journey) that the market lacks.
Q: What is the seed round for?
A: Expansion of clinical operations and technology platform across Delhi NCR — the first market to demonstrate the model before multi-city replication across Mumbai, Bengaluru, and other metros.